NASDAQ
39.95USD
+0.21 (+0.53%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
8.2B
P/E
—
EPS
—
Beta
0.81
52W range
14.32-41.23
Day range
38.95–40.33
Open
39.86
Prev close
39.74
Volume
906.3K
Avg volume
1.8M
Dividend
0.00
IPO
2019-06-21
https://seekingalpha.com/article/4926062-immunovant-risk-reward-setup-compelling-initiating-with-speculative-buy · 7/28/2026+1.00
https://www.defenseworld.net/2026/04/04/immunovant-batoclimab-flops-in-phase-3-ted-as-roivant-expands-brepocitinib-into-lpp.html · 4/4/2026-0.40
https://www.fool.com/coverage/filings/2026/03/15/a-healthcare-hedge-fund-just-added-usd24-5-million-in-immunovant-stock-should-you/ · 3/15/2026+0.60
https://www.zacks.com/stock/news/2841900/imvt-posts-narrower-than-expected-q3-loss-pipeline-in-focus?cid=CS-STOCKNEWSAPI-FT-analyst_blog|earnings_article-2841900 · 2/9/2026+0.40
https://www.zacks.com/stock/news/2827121/wall-street-analysts-predict-a-55-04-upside-in-immunovant-imvt-here-s-what-you-should-know?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|consensus_price_target-2827121 · 2/2/2026
https://www.defenseworld.net/2026/01/18/analyzing-northwest-biotherapeutics-otcmktsnwbo-immunovant-nasdaqimvt.html · 1/18/2026+0.00
https://247wallst.com/investing/2025/12/17/share-offerings-prompt-huge-insider-buying-in-these-3-biotechs/ · 12/17/2025-0.20
https://www.defenseworld.net/2025/12/06/55524-shares-in-immunovant-inc-imvt-purchased-by-capital-fund-management-s-a.html · 12/6/2025+0.20
https://seekingalpha.com/article/4841291-immunovant-inc-imvt-q2-2026-earnings-call-transcript · 11/10/2025+0.00
https://www.zacks.com/stock/news/2747221/imvt-stock-up-11-on-upbeat-batoclimab-hyperthyroidism-study-results?cid=CS-STOCKNEWSAPI-FT-analyst_blog|company_news_medical_sector-2747221 · 9/4/2025+0.80
https://www.globenewswire.com/news-release/2025/09/03/3143957/34323/en/Roivant-Unveils-Durability-and-Treatment-Free-Six-month-Remission-Data-with-Potential-to-Change-Treatment-Paradigm-for-Uncontrolled-Graves-Disease-Patients.html · 9/3/2025+0.80
https://www.zacks.com/stock/news/2702468/immunovant-s-q1-loss-narrower-than-expected-pipeline-in-focus?cid=CS-STOCKNEWSAPI-FT-analyst_blog|earnings_article-2702468 · 8/12/2025-0.20
Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to advancing novel monoclonal antibody therapies for the treatment of various autoimmune conditions. The company's primary focus is batoclimab, a pioneering, fully human monoclonal antibody. This antibody is engineered to specifically target and block the neonatal fragment crystallizable receptor (FcRn), a key mechanism in certain autoimmune diseases. Batoclimab is currently undergoing Phase IIa clinical evaluations for treating both myasthenia gravis and thyroid eye disease. Additionally, it has commenced Phase II clinical studies for patients suffering from warm autoimmune hemolytic anemia. Established in 2018, Immunovant operates from its headquarters in New York, New York, functioning as a subsidiary under the umbrella of Roivant Sciences Ltd.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
